XOMA to Acquire Generation Bio, Expanding Royalty Portfolio and T Cell-Targeted Lipid Nanoparticle Delivery Platform

XOMA Royalty Corporation agreed to acquire Generation Bio Co., a clinical-stage company focused on T cell-driven autoimmune disease, for $4.2913 per share in cash. The acquisition expands XOMA's portfolio with a novel delivery platform and potential future economics from Moderna's collaboration. Generation Bio shareholders will receive a non-transferable contingent value right tied to multiple potential milestones and royalty streams. The transaction is expected to close in February 2026.